ZIMVIE INC Stock Price, News & Analysis

ZimVie Inc. (Nasdaq: ZIMV) has launched its new Immediate Molar Implant System in the United States, expanding its TSX® and T3 PRO® Implant systems portfolio. The innovative system addresses the challenges of replacing extracted molars with implants, offering enhanced precision and control during molar extraction procedures.

The system features specially engineered instrumentation and optimized wide-diameter implants that provide improved primary stability. Its proprietary DAE coronal surface technology potentially reduces peri-implantitis risk by up to 20%. Notably, the system cuts traditional treatment time in half and maintains restorative compatibility with ZimVie's existing implant systems, minimizing switching costs.

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company's management team will deliver a presentation on Tuesday, April 8, 2025 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.

Investors and interested parties can access the live webcast and archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.

ZimVie (Nasdaq: ZIMV), a global dental implant market leader, announced key changes to its Board of Directors. David King, Non-Executive Chair, will not seek reelection when his term expires at the May 7, 2025 shareholders meeting.

Current President and CEO Vafa Jamali will assume the role of Chairman of the Board, while Director Vinit Asar will become Lead Independent Director. Asar, a board member since 2022, currently chairs the Quality, Regulatory, and Technology Committee and serves on the Audit, Corporate Governance, and Compensation Committees.

Under Jamali's leadership since the company's spinoff, ZimVie has transformed into a focused dental company, reduced debt to enhance financial flexibility, and streamlined operations. Asar also serves as Executive Chairman of Hanger, Inc.

ZimVie (NASDAQ: ZIMV) reported its Q4 and FY2024 financial results, marking a transformational year as a pure-play dental company. Full-year 2024 third-party net sales reached $449.7 million, down 1.6% from 2023, with a net loss of $(33.8) million. The company achieved an Adjusted EBITDA of $60.0 million with a 13.3% margin.

In Q4 2024, third-party net sales were $111.5 million, decreasing 1.4% year-over-year, with a net loss of $(9.7) million. However, this represented a $12.5 million improvement from Q4 2023's loss. The quarter's Adjusted EBITDA reached $18.4 million, with a 16.5% margin, showing a 420 basis points increase.

Notable achievements include reducing net debt by over $290 million, streamlining operations through corporate cost reduction, and implementing manufacturing efficiency initiatives. Despite softer end markets, the company improved its Adjusted EBITDA margins by over 4 percentage points in Q4 2024 compared to Q4 2023.

ZimVie Inc (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced it will release its fourth quarter and full-year 2024 financial results after market close on Wednesday, February 26, 2025. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested participants are advised to register online more than 15 minutes before the call begins. A replay of the webcast will be made available on the company's investor relations website.

ZimVie Inc. (NASDAQ: ZIMV) announced the publication of a scientific study in the Journal of Biomedical Materials Research demonstrating the advantages of their dental implant surface technology. The study compared ZimVie's T3® PRO and TSX® Implants' dual acid-etched coronal surface technology with other leading implant brands.

The research identified a critical threshold roughness for dental implants, below which bacterial adhesion remains similar to smooth machined surfaces. ZimVie's implants' coronal surfaces, DAE and Osseotite®, are engineered around this threshold, showing bacterial adhesion levels comparable to machined surfaces while maintaining crestal bone levels similar to rougher surfaces.

The findings suggest that ZimVie's implants may help reduce the risk of peri-implant infections compared to other commercial implants, addressing the growing concern of peri-implant mucositis and peri-implantitis in dental implantology.

ZimVie Inc. (ZIMV) reported Q3 2024 financial results with third-party net sales of $103.2 million, showing a 2.0% decrease from Q3 2023. The company posted a net loss of $(3.0) million, improving from a $(10.2) million loss in the previous year. Adjusted EBITDA reached $13.1 million with a 12.7% margin, up 110 basis points year-over-year. The company reported GAAP diluted EPS of $(0.11) and adjusted diluted EPS of $0.12. ZimVie updated its full-year 2024 guidance, projecting net sales between $450M to $455M and adjusted EBITDA between $60M to $62M.

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced its participation in the upcoming UBS Global Healthcare Conference. The company's management will deliver a presentation on Tuesday, November 12, 2024, at 3:30 p.m. Eastern Time / 12:30 p.m. Pacific Time.

Interested parties can access both the live webcast and an archived recording of the presentation through ZimVie's investor website at investor.zimvie.com.

ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, has announced that it will report its third quarter 2024 financial results after market close on Wednesday, October 30, 2024. The company will host a conference call to discuss the results, beginning at 4:30 p.m. Eastern Time on the same day.

Interested parties can register for the conference call online. It is recommended to register more than 15 minutes before the call starts. For those unable to attend the live call, a replay of the webcast will be made available on the company's investor relations website at investor.zimvie.com.